NHS England
Printable version

NHS to fast-track patients with head and neck cancer into cancer vaccine trial

Patients with advanced head and neck cancers in England will be fast-tracked into a trial of a new cancer vaccine, as the NHS expands its world-leading trial ‘match-making’ service.

The investigational cancer vaccine uses mRNA technology to help the immune system recognise and kill cancer cells containing human papillomavirus proteins.

More than 100 patients with advanced head and neck cancer in England will be matched to the trial, running at 15 NHS hospitals over the next year, supported by the NHS’ Cancer Vaccine Launch Pad (CVLP).

This is the third cancer vaccine trial to be run through the NHS Cancer Vaccine Launch Pad, coordinated by the Southampton Clinical Trials Unit, which has already helped refer around 550 patients to trials of vaccines for bowel and skin cancers.

The first head and neck cancer patients in England have received the investigational mRNA cancer vaccine in the clinical trial, known as AHEAD-MERIT (BNT113-01), with more patients to soon be enrolled at their nearest NHS hospital.

More than 11,000 new head and neck cancer cases are diagnosed in England every year, with cancers typically developing in the mouth, throat or voice box.

Despite advances in care for patients with head and neck cancer, the advanced form of the disease is difficult to treat and has high rates of recurrence, with two-year survival rates at under 50%.

The investigational cancer vaccine is designed to encode two proteins that are frequently found in head and neck squamous cell cancers associated with human papillomavirus (HPV-16), the most common type of head and neck cancer (accounting for 95% of these types of cancers), with the vaccine training the immune system to fight the cancer.

NHS England is partnering with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the clinical trial.

Professor Peter Johnson, NHS England National Clinical Director for cancer, said: “It’s fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay.

“The NHS is always looking for evidence-backed innovations in treatment to improve survival and quality of life for people diagnosed with cancer, and this expansion of our Cancer Vaccine Launch Pad will give hundreds of patients the chance to be part of cutting-edge advances in cancer care”.

Chris Curtis, 67 years old, from Blackpool, was diagnosed with HPV related head and neck cancer in 2011 and set up a support charity, The Swallows. He said: “As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them.

“When I was diagnosed with stage four tongue cancer and two secondary cancers, one each side of the neck, my world just fell apart. I then had to go through brutal treatment, including six weeks of radiotherapy, chemotherapy every week, two neck dissections and be fed on a tube for almost three years. I lost 12 stone in weight and was severely physically and mentally unwell.

“With this aggressive cancer you live in fear every day – so anything that could help control the disease or give people peace of mind is ground-breaking – it’ll allow people to get on with their lives and move forward”.

Minister for Health Karin Smyth said: “This is a massive win for cancer patients – and is exactly the kind of innovation we’re aiming to deliver with our 10 Year Health Plan.

“These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. By getting these trials running in our NHS, we’re putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer.

“With our Plan for Change, we’re building an NHS that’s fit for future – one that is committed to transforming how cancer is treated and helping people to live longer”.

Science Minister Lord Vallance said: “Advancements in cancer research offer patients hope for a better quality of life, and a better chance of survival. This clinical trial is an important milestone for an exciting new approach for patients living with head and neck cancer.

“Our partnership with BioNTech is delivering for patients right across the country, and I hope to see more ambitious work like this as they continue to invest in Research and Development and AI as part of their billion-pound backing for the UK over the next ten years. We’re determined to work closely with leading life sciences companies like BioNTech, to drive this thriving sector to even greater heights as part of our modern Industrial Strategy”.

Tamara Kahn, CEO at Oracle Head and Neck Cancer UK, said: “With two-thirds of head and neck cancer patients diagnosed at late stage and facing survival rates under 50% at two years, this cancer vaccine trial offers crucial hope to those living advanced stages of cancer.

“While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones.

“We’re encouraged by the NHS’s commitment to fast-tracking eligible patients into this trial and look forward to working with them and the Department of Health in potentially improving outcomes for those facing this challenging cancer”.

The CVLP is part of a strategic partnership between NHS England, the Government and BioNTech. It has been instrumental in accelerating trial activity in cancer research, with CVLP sites driving faster activation and enrolment timelines compared to a typical clinical trial process, enabling the acceleration of one recent study by nearly a year.

The ambitious programme aims to match thousands more cancer patients with cancer vaccine and immunotherapy trials for different types of cancer in future.

Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK, said: “The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. It’s great to see more clinical trials of vaccines for head and neck cancer supported by the Cancer Research UK-funded Southampton Clinical Trials Unit.

“Research into personalised cancer treatments is vital. There are over 200 different types of cancer and it’s unlikely there will ever be a single cure that works for everyone. That’s why it’s vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer”.

Dr Victoria Goss, Associate Professor of Early Diagnosis and Translational Research at the Southampton Clinical Trials Unit, said: “We are delighted to bring this latest trial onto the CVLP programme and give more people with advanced head and neck cancer the chance to take part in this exciting research.

“Our trials unit has great expertise in this area having run the very early phase trial of this experimental cancer vaccine, and it is fantastic to be working with BioNTech again to continue developing this potential new cancer treatment”.

Channel website: https://www.england.nhs.uk/

Original article link: https://www.england.nhs.uk/2025/08/nhs-to-fast-track-patients-with-head-and-neck-cancer-into-cancer-vaccine-trial/

Share this article

Latest News from
NHS England

NHS rolls out discreet home-testing kits against cervical cancer for millions of women

25/08/2026 13:10:00

Nearly 4 million women will be offered HPV self-testing kits if they have not attended cervical screening appointments following invitations from the NHS in England.

The NHS is starting to roll out the new self-testing kits from today to encourage more women to complete their potentially lifesaving screening to detect human papillomavirus (HPV), which can increase the risk of cervical cancer.

England’s leading women’s health doctor described the move as a “gamechanger” given that around a third of those eligible aren’t up to date with their cervical screening, and this test provides a more “discreet and convenient option” for them.

The self-testing kit contains a swab, similar to a long cotton bud, which is used to collect a sample from the vagina. The sample is then posted back to the NHS for free, where it is checked for high-risk HPV.

If high-risk HPV is found, individuals will be invited to book a follow-up cervical screening appointment at their GP surgery or sexual health clinic, where a nurse or doctor will take a small sample from the cervix to check for cell changes.

Cervical screening helps prevent cervical cancer by checking for high-risk types of HPV. It is a common virus that can cause changes to cells in the cervix. These changes can usually be treated before cancer develops.

Women who are eligible will start receiving invitations today via the NHS App, text message, email or letter, and once invited they will be able to order a free kit through the NHS App or their NHS online account.

This is the next major step the NHS is taking in its pledge to eliminate cervical cancer by 2040, by making it as easy as possible for people to get the lifesaving HPV vaccination and increasing cervical screening attendance.

Dr Sue Mann, National Clinical Director for Women’s Health at NHS England, said: “Screening saves thousands of lives each year by preventing cancers and catching them earlier, but only around two-thirds of women are attending cervical screening appointments when invited by the NHS.

“Offering millions of women an alternative test they can do from the comfort of their own homes will be a gamechanger – making it easier than ever for them to get tested for HPV. 

“There are lots of reasons that may stop women from getting their cervical screening – embarrassment, lack of time, or worries about discomfort – and these kits provide a discreet and convenient option we hope will encourage more women to take up the life-saving test. 

“So, if you’re invited to take part, please order a test – it’s a simple swab you can do at home in minutes.”

Cervical screening appointments with a clinician remain the best way to help prevent cervical cancer, but HPV self-testing is being introduced by the NHS as an additional choice for people who have not taken up previous invitations.

HPV self-testing is an invitation-only offer and is being rolled out in phases across England as part of the NHS Cervical Screening Programme, starting with those aged between 30 and 65, who have not attended cervical screening following previous invitations.

The national rollout comes on the back of the YouScreen trial run by North London cancer alliances in collaboration with NHS England and King’s College London in 2021, which found offering self-testing kits to under-screened women at their GP practice or at home could boost the numbers screened in England by about 400,000 each year.

The UK National Screening Committee used evidence from this trial in its recommendation to roll this out wider.

The latest figures show that 68.8% of eligible women were up to date with their cervical screening – below the NHS England target of 80%. This means around 4 million women in England are not up to date with their routine check-up.

Women aged 24-64 are invited for cervical screening by the NHS every five years, or more frequently if HPV is detected.

Anyone who has been invited for cervical screening can still book an appointment at any time, even if the invitation was sent months or years ago.

It is still important to attend cervical screening appointments if you have been vaccinated against HPV as the vaccine does not provide protection from all types of HPV, so there is a still a small chance of getting cervical cancer.

People who routinely attend for a cervical screening test with a clinician at their GP practice or sexual health clinic should continue to book their appointments as normal.

Health and Social Care Secretary Yvette Cooper said: “Cervical cancer is preventable – but that’s why we want to make it as easy and convenient as possible for women to keep up with their screening.

“These free self-testing kits will be offered to four million women who are currently behind on their screening to make it easier for as many women as possible to keep themselves healthy and safe.

“This is the future NHS we are building – there for all of us when we need it, and acting as early as possible to stop preventable deaths.”

Cancer Research UK’s Chief Executive, Michelle Mitchell, said: “Cervical screening is a powerful tool that saves lives – it can prevent cervical cancer or spot it at an earlier stage when treatment is more likely to be successful. 

“While it’s best for cervical screening to be done by a nurse or doctor, there are barriers that make it challenging for some people to attend. At-home HPV self-testing kits will help more people take part in a way that works for them.

“If people receive their cervical screening or self-testing kit invitation, please consider taking up the offer and encourage loved ones to do the same. Beating cervical cancer means beating it for everyone, and this move brings us closer to that goal.”

Athena Lamnisos, Chief Executive Officer at The Eve Appeal, said: “There are many reasons why those eligible for cervical screening don’t attend.

“Challenges around the type of test it is, limited awareness around HPV and its role in cancer development, as well as practical barriers such as problems around booking and attending an appointment, stop many from going.

“Cervical screening is designed to prevent cervical cancer rather than respond to symptoms, attending a clinic requires people to actively prioritise an appointment among the many competing demands of everyday life.

“Self-testing which can be done at home will be a step-change for many. We have the incredible opportunity to see the back of cervical cancer. How brilliant would that be? But to achieve this, we need to support everyone eligible to attend screening.

“At Eve we welcome the rollout of this programme and its focus on the audiences who need it most in the first stage of the screening pathway. Looking to the future, we hope that self-testing will provide the under-screened and never screened with a new option to help address some of the key barriers. 

“This is not a replacement for clinician screening, and we will continue to work with and support those attending their traditional cervical screening, to help make their appointments more comfortable and accessible. 

“The NHS has set a 2040 target for eliminating cervical cancer. We hope that rolling out self-testing will help us reach it.”

Dawn Bryant, 62, from Hertfordshire, had cancerous cells found early thanks to NHS cervical screening and feels extremely lucky that it was detected and treated before the cancer progressed any further.

She says cervical screening may have saved her life and is encouraging other women who haven’t had theirs yet or have put it off, to book an appointment or do the at-home HPV test if invited.

“My nan died of cervical cancer when I was only 11 so I know how difficult it can be and how important cervical screening is.

“A screening test when I was 32 found I had severe high-grade cell changes, and after further testing I was told it was cancer. 

“I am so lucky it was found at an early stage and could be easily treated. I had some surgery to remove the cells, but I didn’t have to have chemotherapy, radiotherapy, or anything. It was a very scary time, but who knows what would have happened if I’d delayed having the test. 

“Since then, I have been regularly monitored, and had many tests and colposcopies, and although they can be a bit uncomfortable, I would not think twice about having them done again.

“I know lots of women who have put off having screening, and sadly, some who have been diagnosed with advanced cervical cancer after putting it off for years.

“It is so important women go for these check-ups or do the home-testing kit if invited. It doesn’t take very long and if you’re worried or have questions, the staff are excellent and will talk to you and help answer any fears you’ve got.”